Records 1 - 5 (of 5 Records) |
Query Trace: Muscular dystrophy[original query]>>Ethical, Legal and Social Issues (ELSI)[Category] |
---|
Food and Drug Administration Lifts Clinical Hold on Pfizer Duchenne Muscular Dystrophy Gene Therapy Linked to Patient Death. Philippidis Alex et al. Human gene therapy 2022 33(11-12) 573-576 |
The good, the bad, and the utilitarian: attitudes towards genetic testing and implications for disability. Maftei Alexandra et al. Current psychology (New Brunswick, N.J.) 2022 1-22 |
[Clinical Ethics in Hereditary Neuromuscular Diseases such as Duchenne Muscular Dystrophy]. Nakajima Takashi et al. Brain and nerve = Shinkei kenkyu no shinpo 2020 Jul 72(7) 753-766 |
Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy. Kesselheim Aaron S et al. JAMA 2016 Oct |
Ethical and Policy Issues in Newborn Screening of Children for Neurologic and Developmental Disorders. Ross Lainie Friedman et al. Pediatr. Clin. North Am. 2015 Jun 62(3) 787-798 |